Lantheus Holdings, Inc. · NASDAQ:LNTH
Lantheus — Q2 2024 Earnings Presentation
30 slides from Lantheus's earnings presentation, Jul 31, 2024
Slide 1: Lantheus Second Quarter 2024 Results
Lantheus Second Quarter 2024 Results July 31, 2024 FIND. FIGHT. FOLLOW. ® © 2024 Lantheus. All rights reserved.
Slide 2: Speakers and Agenda
SPEAKERS AGENDA Highlights & Business Update Operational Update Brian Markison Paul Blanchfield Bob Marshall Mark Kinarney CEO President CFO and Treasurer Vice President, Investor Relations Financial Update Q&A Closing Remarks Q&A Jeff Humphrey, MD Amanda Morgan Chief Medical Officer Chief Commercia
Slide 3: Safe Harbor Statements
Safe Harbor Statements Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe har
Slide 4: Agenda
AGENDA SPEAKERS Highlights & Business Update Operational Update Brian Markison Paul Blanchfield Bob Marshall Mark Kinarney CEO President CFO and Treasurer Vice President, Investor Relations Financial Update Q&A Closing Remarks Q&A Jeff Humphrey, MD Amanda Morgan Chief Medical Officer Chief Commercia
Slide 5: 2Q 2024: Continued Strong Performance
Lantheus: The Leading Radiopharmaceutical-Focused Company 2Q 2024: Continued Strong Performance Strong Revenue and Total Revenue: $394.1M (+22.5%) Earnings1 Adjusted EPS: $1.80 (+16.4%) Sustained Growth PYLARIFY remains the clear market leader in PSMA PET imaging2 Across Commercial →Potential >$1B s
Slide 6: Expanding Innovative Pipeline of Radiopharmaceuticals
Expanding Innovative Pipeline of Radiopharmaceuticals Candidate Target Isotope Indication/Disease Area Pre-Clinical Phase I Phase II Phase III Reg. Filling PNT20021 PSMA 177Lu Metastatic Prostate Cancer Prostate LNTH-24012 GRPR 68Ga Metastatic Prostate Cancer Cancer LNTH-24023 GRPR 177Lu Metastatic
Slide 7: Expanding Innovative Pipeline of Radiopharmaceuticals
Expanding Innovative Pipeline of Radiopharmaceuticals LNTH-2401 & LNTH-2403 & NAV-4694 LNTH-2402 LNTH-2404 (flutafuranol) Next-Generation ß Amyloid F18 PET Novel Therapeutic and Diagnostic Innovative Pre-clinical Assets Targeting Imaging Agent for Alzheimer’s Pair Targeting GRPR for Prostate & Solid
Slide 8: Agenda
AGENDA SPEAKERS Highlights & Business Update Operational Update Brian Markison Paul Blanchfield Bob Marshall Mark Kinarney CEO President CFO and Treasurer Vice President, Investor Relations Financial Update Q&A Closing Remarks Q&A Jeff Humphrey, MD Amanda Morgan Chief Medical Officer Chief Commercia
Slide 9: PYLARIFY: $273.3M, +29.8% Growth
Utilized PSMA PET Imaging Agent2 $273.3M +29.8% Growth 2Q 2024 Net Sales Year-over-Year PYLARIFY delivers a best-in-class customer experience Driving growth and demand through continued education to the prostate cancer community 1. PYLARIFY® [package insert]. North Billerica, MA: Progenics Pharmaceu
Slide 10: Sustaining Brand Leadership
Sustaining Brand Leadership Multifaceted Market Access strategy • Clinical and commercial differentiation through educational and promotional efforts Only widely available PSMA PET • Long-term strategic partnerships with key customers imaging agent through diverse F18 distributor network • CY2025 pr
Slide 11: DEFINITY: $78.1M, +10.7% Growth
Drivers of $78.1M Success 2Q 2024 Net Sales • Clinical and commercial value proposition +10.7% Growth • Decades of experience in clinical use Year-over-Year • Operational excellence The Clear Market Leader in the U.S. Ultrasound Enhancing Agent Market2 1. DEFINITY is indicated, after activation, for
Slide 12: Late Stage Radiotherapeutic and Radiodiagnostic Pipeline Programs
Late Stage Radiotherapeutic and Radiodiagnostic Pipeline Programs PNT2002 PNT2003 MK-6240 NAV-4694 Late-stage, PSMA-targeted Registrational-stage, Somatostatin Novel, late-stage, Tau Novel, late-stage, β Amyloid radiotherapeutic for mCRPC receptor (SSTR)–targeted radiotherapeutic radiodiagnostic for
Slide 13: Agenda
AGENDA SPEAKERS Highlights & Business Update Operational Update Brian Markison Paul Blanchfield Bob Marshall Mark Kinarney CEO President CFO and Treasurer Vice President, Investor Relations Financial Update Q&A Closing Remarks Q&A Jeff Humphrey, MD Amanda Morgan Chief Medical Officer Chief Commercia
Slide 14: Continued Strong Financial Performance in 2Q 2024
Continued Strong Financial Performance in 2Q 2024 USD Millions Total Revenue Other Precision Diagnostics Strategic Partnerships & Other +22.5% +$72.4 TechneLite INCREASE $28.2 (+30.5%) DEFINITY $394.1 $78.1 (+10.7%) PYLARIFY $321.7 $273.3 (+29.8%) 2Q 2023 2Q 2024 © 2024 Lantheus. All rights reserved
Slide 15: 2Q 2024 Financial Highlights
2Q 2024 Financial Highlights1 Adjusted Net Income Adjusted EPS USD Millions USD +15.7% +$0.25 +16.4% +$17.2 INCREASE INCREASE $126.8 $1.80 $1.54 $109.6 2Q 2023 2Q 2024 2Q 2023 2Q 2024 Cash and Cash Equivalents as of June 30, 2024: $757.0M 1. See slide 26 for a reconciliation of GAAP to non-GAAP fina
Slide 16: Growing Capital Resources Provide Financial Flexibility
Growing Capital Resources Provide Financial Flexibility1 USD Millions Cash Flow Summary Free Cash Flow2 Resources Three Months Ending June 30 (2Q 2024) 2023 2024 +$116.5 INCREASE Cash (used in) provided by ($32.3) $84.7 $757.0 operations $73.5 CASH ON HAND3 Cash used in ($20.7) ($45.1) investing ($4
Slide 17: Updated FY 2024 Financial Guidance
Updated FY 2024 Financial Guidance1 The Company guidance for the full year 2024 is as follows: Prior Revenue $1.50B – $1.52B Current Revenue $1.50B – $1.52B FY 2024 Prior Adjusted Fully Diluted EPS2 $7.00 – $7.20 Current Adjusted Fully Diluted EPS2 $6.60 – $6.70 Guidance Issued July 31, 2024 Affirms
Slide 18: Agenda
AGENDA SPEAKERS Highlights & Business Update Operational Update Brian Markison Paul Blanchfield Bob Marshall Mark Kinarney CEO President CFO and Treasurer Vice President, Investor Relations Financial Update Q&A Closing Remarks Q&A Jeff Humphrey, MD Amanda Morgan Chief Medical Officer Chief Commercia
Slide 19: Lantheus, the Leading Radiopharmaceutical-Focused Company
Lantheus, the Leading Radiopharmaceutical-Focused Company Maximize the value of our existing portfolio and expand our innovative pipeline of radiopharmaceuticals STRATEGY: through focused business development and M&A, all while sustaining an attractive financial profile Executing on Focused Strategy
Slide 20: Agenda
SPEAKERS AGENDA Highlights & Business Update Operational Update Brian Markison Paul Blanchfield Bob Marshall Mark Kinarney CEO President CFO and Treasurer Vice President, Investor Relations Financial Update Q&A Closing Remarks Q&A Jeff Humphrey, MD Amanda Morgan Chief Medical Officer Chief Commercia
Slide 21: Appendix
Appendix © 2024 Lantheus. All rights reserved. 21
Slide 22: Condensed Consolidated Statement of Operations – 2Q 2024
Condensed Consolidated Statement of Operations – 2Q 2024 © 2024 Lantheus. All rights reserved. 22
Slide 23: As Adjusted Condensed Consolidated Statement of Operations – 2Q 2024
As Adjusted Condensed Consolidated Statement of Operations – 2Q 2024 © 2024 Lantheus. All rights reserved. 23
Slide 24: Condensed Consolidated Statement of Operations – FY 2Q 2024
Condensed Consolidated Statement of Operations – FY 2Q 2024 © 2024 Lantheus. All rights reserved. 24
Slide 25: As Adjusted Condensed Consolidated Statement of Operations – FY 2Q 2024
As Adjusted Condensed Consolidated Statement of Operations – FY 2Q 2024 © 2024 Lantheus. All rights reserved. 25
Slide 26: Reconciliation of GAAP to Non-GAAP Financial Measures
Reconciliation of GAAP to Non-GAAP Financial Measures (in thousands, except per share data – unaudited) © 2024 Lantheus. All rights reserved. 26
Slide 27: Consolidated Statement of Operations
Consolidated Statement of Operations (in thousands, except per share data – unaudited) © 2024 Lantheus. All rights reserved. 27
Slide 28: Consolidated Segment Revenues Analysis
Consolidated Segment Revenues Analysis (in thousands – unaudited) © 2024 Lantheus. All rights reserved. 28
Slide 29: Reconciliation of Free Cash Flow
Reconciliation of Free Cash Flow (in thousands – unaudited) © 2024 Lantheus. All rights reserved. 29
Slide 30: Condensed Consolidated Balance Sheet
Condensed Consolidated Balance Sheet (in thousands – unaudited) © 2024 Lantheus. All rights reserved. 30